Return to study ST001097 main page

MB Sample ID: SA074831

Local Sample ID:V209
Subject ID:SU001141
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:30-60 years old
Weight Or Weight Range:52.3-176.6 kg
Gender:Male and female
Human Medications:To be included in the study all participants had to be taking an atypical (second generation) antipsychotic
Human Inclusion Criteria:DSM IV diagnosis of a schizophrenia spectrum diagnosis who had been taking an atypical antipsychotic for at least 6 months, with no changes in antipsychotic regimen for 8 weeks preceding the baseline visit. Twenty age and sex matched obese and nonobese participants without mental health diagnoses were included to match the BMI range of the patients with schizophrenia as BMI controls.
Human Exclusion Criteria:Current use of insulin, diagnosis of diabetes mellitus type 2 prior to antipsychotic exposure, active substance abuse diagnosis

Select appropriate tab below to view additional metadata details:

Sample Preparation:

Sampleprep ID:SP001148
Sampleprep Summary:Serum samples were subjected to a 1:1 methanol:chloroform extraction, then lyophilized. Prior to NMR the aqueous fraction samples were resuspended and filtered. Prior to fatty acid analysis the lipid fractions were resuspended and purified by TLC prior to GC analysis. This is described in more detail in the attached document.
Sampleprep Protocol ID:EllingrodSamplePrepProtocol
Processing Method:methanol:chloroform extraction, filtration
Processing Storage Conditions:4?
Extraction Method:methanol:chloroform
Extract Enrichment:ultra-filtration (3kDa filters) to remove residual protein
Extract Cleanup:N/A
Extract Storage:-80?
Sample Resuspension:500uL deuterium oxide for aqueous fraction, lipid fraction was resuspended in hexane prior to GC analysis
Sample Spiking:aqueous fraction: CaFormate 12mM, lipid faction: C17:0 methyl ester
  logo